Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
This study has been completed.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: January 16, 2007
Last updated: June 17, 2012
Last verified: January 2009
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||February 2009 (Final data collection date for primary outcome measure)|
Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct;24(10):2548-54. doi: 10.1093/annonc/mdt213. Epub 2013 Jun 24.